Efferon wants to eradicate the devastating toll of pediatric sepsis

Efferon, a startup founded by a former Battlefield 200 player, is developing a blood-purification technology to treat pediatric sepsis with the goal of reducing the devastating toll it takes on children. The technology has shown promising results in preclinical trials, with a 100% survival rate in a 12-hour model of sepsis. Efferon is currently raising $2 million in seed funding to further its research and development. The company's co-founder, David, has a personal connection to the issue, having experienced the loss of a friend to sepsis. Efferon's technology uses a proprietary membrane to remove toxins and inflammatory mediators from the blood, which are key contributors to sepsis. The startup has partnered with a hospital to conduct a human clinical trial in 2023.